Quantification of prostate MRSI data by model-based time domain fitting and frequency domain analysis

NMR in Biomedicine

Volumn 19, Issue 2, 2006, Pages 188-197

  Pels, Pieter ^a,b   Osturk Isik, Esin ^b,c   Swanson, Mark G ^b   Vanhamme, Leentje ^a   Kurhanewicz, John ^b   Nelson, Sarah J ^b,c   Van Huffel, Sabine ^a  

^a UNIVERSITY OF LEUVEN   (Belgium)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UCSF/UCB Joint Graduate Group in Bioengineering   (United States)

Author keywords

Choline polyamines; Citrate; Frequency domain; MR spectroscopy; Prostate cancer; Quantification; Time domain

Indexed keywords

COMPUTER SIMULATION; CURVE FITTING; FREQUENCY DOMAIN ANALYSIS; MAGNETIC RESONANCE SPECTROSCOPY; MEDICAL IMAGING; MONTE CARLO METHODS; SPECTRUM ANALYSIS; TIME DOMAIN ANALYSIS;

CHOLINE POLYAMINES; CITRATE; CREATINE; PROSTATE CANCER; TIME DOMAIN FITTING METHOD;

BIOMEDICAL ENGINEERING;

CHOLINE; CITRIC ACID; CREATINE; POLYAMINE;

ALGORITHM; ANALYTIC METHOD; ARTICLE; ARTIFACT; CANCER TISSUE; CASE STUDY; CONTROLLED STUDY; DATA ANALYSIS; DIAGNOSTIC ACCURACY; EMPIRICISM; FREQUENCY ANALYSIS; IMAGING SYSTEM; IN VIVO STUDY; INTERMETHOD COMPARISON; MALIGNANT NEOPLASTIC DISEASE; MATHEMATICAL MODEL; MONTE CARLO METHOD; NONLINEAR SYSTEM; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PHANTOM; PRIORITY JOURNAL; PROSTATE CANCER; QUANTITATIVE ANALYSIS;

ALGORITHMS; COMPUTER SIMULATION; DATABASES, FACTUAL; DIAGNOSIS, COMPUTER-ASSISTED; FOURIER ANALYSIS; HUMANS; MAGNETIC RESONANCE IMAGING; MAGNETIC RESONANCE SPECTROSCOPY; MALE; MODELS, BIOLOGICAL; PHANTOMS, IMAGING; PROSTATIC NEOPLASMS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; TIME FACTORS; TUMOR MARKERS, BIOLOGICAL;

EID: 33645520844     PISSN: 09523480     EISSN: 10991492     Source Type: Journal    
DOI: 10.1002/nbm.1008     Document Type: Article

References (31)

1. The American Cancer Society. Cancer Facts and Figures, 2004.
2. Dhingsa R, Qayyum A, Coakley FV, Lu Y, Jones KD, Swanson MG, Carroll PR, Hricak H, Kurhanewicz J. Prostate cancer localization with endorectal MR imaging and MR spectroscopic imaging: effect of clinical data on reader accuracy. Radiology 2004; 230(1): 215-220.
3. Scheidler J, Hricak H, Vigneron DB, Yu KK, Sokolov DL, Huang LR, Zaloudek CJ, Nelson SJ, Carroll PR, Kurhanewicz J. Prostate cancer: localization with three-dimensional proton MR spectroscopic imaging - clinicopathologic study. Radiology 1999; 213(2): 473-480.
4. Yu KK, Scheidler J, Hricak H, Vigneron DB, Zaloudek CJ, Males RG, Nelson SJ, Carroll PR, Kurhanewicz J. Prostate cancer: prediction of extracapsular extension with endorectal MR imaging and three-dimensional proton MR spectroscopic imaging. Radiology 1999; 213(2): 481-488.
5. Kurhanewicz J, Swanson MG, Nelson SJ, Vigneron DB. Combined magnetic resonance imaging and spectroscopic imaging approach to molecular imaging of prostate cancer. J. Magn. Reson. Imag. 2002; 16(4): 451-463.
6. Coakley FV, Kurhanewicz J, Lu Y, Jones KD, Swanson MG, Chang SD, Carroll PR, Hricak H. Prostate cancer tumor volume: measurement with endorectal MR and MR spectroscopic imaging. Radiology 2002; 223(1): 91-97.
7. Kurhanewicz J, Swanson MG, Wood PJ, Vigneron DB. Magnetic resonance imaging and spectroscopic imaging: improved patient selection and potential for metabolic intermediate endpoints in prostate cancer chemoprevention trials. Urology 2001; 57(4, suppl. A): 124-128.
8. DiBiase SJ, Hosseinzadeh K, Gullapalli RP, Jacobs SC, Naslund MJ, Sklar GN, Alexander RB, Yu C. Magnetic resonance spectroscopic imaging-guided brachytherapy for localized prostate cancer. Int. J. Radiat. Oncol. Biol. Phys. 2002; 52(2): 429-438.
9. Zaider M, Zelefsky MJ, Lee EK, Zakian KL, Amols HI, Dyke J, Cohen G, Hu Y, Endi AK, Chui C, Koutcher JA. Treatment planning for prostate implants using magnetic-resonance spectroscopy imaging. Int. J. Radiat. Oncol. Biol. Phys. 2000; 47(4): 1085-1096.
10. Zelefsky MJ, Cohen G, Zakian KL, Dyke J, Koutcher JA, Hricak H, Schwartz L, Zaider M. Intraoperative conformal optimization for transperineal prostate implantation using magnetic resonance spectroscopic imaging. Cancer J. 2000; 6(4): 249-255.
11. Parivar F, Hricak H, Shinohara K, Kurhanewicz J, Vigneron DB, Nelson SJ, Carroll PR. Detection of locally recurrent prostate cancer after cryosurgery - evaluation by transrectal ultrasound, magnetic resonance imaging, and three-dimensional proton magnetic resonance spectroscopy. Urology 1996; 48(4): 594-599.
12. Mueller-Lisse UG, Swanson MG, Vigneron DB, Hricak H, Bessette A, Males RG, Wood PJ, Noworolski S, Nelson SJ, Barken I, Carroll PR, Kurhanewicz J. Time-dependent effects of hormone-deprivation therapy on prostate metabolism as detected by combined magnetic resonance imaging and 3D magnetic resonance spectroscopic imaging. Magn. Reson. Med. 2001; 46(1): 49-57.
13. 1H MR spectroscopy and MR imaging: clinicopathologic case-controlled study. Radiology 2001; 221(2): 380-390.
14. Pickett B, Kurhanewicz J, Fein B, Coakley F, Shinohara K, Roach M. Use of magnetic resonance imaging and spectroscopy in the evaluation of external beam radiation therapy for prostate cancer. Int. J. Radiat. Oncol. Biol. Phys. 2003; 57(2 suppl.): S163-S164.
15. Coakley FV, Teh HS, Qayyum A, Swanson MG, Lu Y, Roach M, Pickett B, Shinohara K, Vigneron DB, Kurhanewicz J. Endorectal MR and MR spectroscopic imaging of locally recurrent prostate cancer after external beam radiation therapy: preliminary experience. Radiology 2004; 233(2): 441-448.
16. Ackerstaff E, Pflug BR, Nelson JB, Bhujwalla ZM. Detection of increased choline compounds with proton nuclear magnetic resonance spectroscopy subsequent to malignant transformation of human prostatic epithelial cells. Cancer Res. 2001; 61: 3599-3603.
17. Kurhanewicz J, Swanson MG, Nelson SJ, Vigneron DB. Combined magnetic resonance imaging and spectroscopic imaging approach to molecular imaging of prostate cancer. J. Magn. Reson. Imag. 2002; 16: 451-463.
18. Costello LC, Franklin RB, Narayan P. Citrate in the diagnosis of prostate cancer. Prostate 1999; 38(3): 237-245.
19. 13C-1 NMR signal. NMR Biomed. 1996; 9(7): 315-321.
20. 31P MRS: absolute concentrations, signal-to-noise and prior knowledge. NMR Biomed. 1995; 8(2): 87-93.
21. 1H spectra of lipoproteins. Magn. Reson. Med. 1994; 31(4): 347-358.
22. 1H human brain spectra by LCModel and AMARES. Magn. Reson. Med. 2004; 51(5): 904-912.
23. Elster C, Link A, Schubert F, Seifert F, Walzel M, Rinneberg H. Quantitative MRS: comparison of time domain and time domain frequency domain methods using a novel test procedure. Magn. Reson. Imag. 2000; 18(5): 597-606.
24. 1H-MRS measurements in schizophrenic patients. Magn. Reson. Med. 2003; 50(4): 704-707.
25. De Beer R, Van den Boogaart A, Cady E, Graveron-Demilly D, Knijn A, Langenberger KW, London JC, Ohlhoff A, Serrai H, Wylezinska-Arridge M. Absolute metabolite quantification by in vivo NMR spectroscopy: V. Multicentre quantitative data analysis trial on the overlapping background problem. Magn. Reson. Imag. 1998; 16(9): 1127-1137.
26. Vanhamme L, van den Boogaart A, Van Huffel S. Improved method for accurate and efficient quantification of MRS data with use of prior knowledge. J. Magn. Reson. 1997; 129(1): 35-43.
27. 1H spectra: from finite impulse response filter design for solvent suppression to parameter estimation. J. Magn. Reson. 1999; 139(2): 189-204.
28. Nelson SJ. Analysis of volume MRI and MR spectroscopic imaging data for the evaluation of patients with brain tumors. Magn. Reson. Med. 2001; 46(2): 228-239.
29. Star-Lack J, Nelson SJ, Kurhanewicz J, Huang LR, Vigneron DB. Improved water and lipid suppression for 3D PRESS CSI using RF band selective inversion with gradient dephasing (BASING). Magn. Reson. Med. 1997; 38(2): 311-321.
30. Mulkern RV, Bowers JL. Calculating spectral modulations of AB systems during PRESS acquisitions. Magn. Reson. Med. 1993; 30(4): 518.
31. Söderström T, Stoica P. System Identification. Prentice-Hall: London, 1998.